Could myeloma-associated antibodies could one day serve as biomarkers for predicting which patients will benefit from isatuximab?
An antibody-drug conjugate showed antitumor activity in preclinical models for pancreatic cancer, among other cancer types, leading to a phase 1 clinical trial.
“Despite a lack of head-to-head trials, there is a perception that irAE profiles are
comparable between agents,” the abstract authors wrote.
More than 15,000 distinct irAEs were found for 13,030 patients.
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Antibiotic therapy administered prior to treatment with ICIs was negatively associated with OS across tumor types, as well as tumor response, the researchers noted.
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
The problem of low representation of racial minorities is especially urgent during the era of immunotherapy trials.
KEYNOTE-024 shows first-line pembrolizumab has long-term overall survival benefit in patients with advanced non-small cell lung cancer and PD-L1–expressing disease.
Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.
